Drugs / HSK21542
Trials 18
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT06238388 | Oct → Nov 2023 | chronic kidney disease | Haisco Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05947097 | Apr → Jul 2023 | impaired renal function disease | Haisco Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05835934 | Jun → Sep 2021 | — | Haisco Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04110886 | Jul → Dec 2020 | chronic pain syndrome | Sichuan Haisco Pharmaceutical Group Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT04213196 | Jan → Sep 2020 | — | Sichuan Haisco Pharmaceutical Group Co., Ltd | Completed | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT06593782 | Sep 2024 → Jun 2025 overdue | chemotherapy-induced toxicity | First Affiliated Hospital of Wenzhou Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07442877 | Sep 2024 → Jan 2025 | — | Haisco Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT06290375 | Mar 2024 | — | Xizang Haisco Pharmaceutical Co., Ltd | Unknown | No outcome recorded |
| Phase 2 | NCT04999787 | Sep 2021 → Aug 2022 | — | Haisco Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04470128 | Aug → Dec 2020 | — | Haisco Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04470154 | Aug 2020 → Oct 2021 | — | Haisco Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04424251 | Jul → Dec 2020 | — | Haisco Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 34 trials · 2 met primary | ||||||
| Phase 3 | NCT07186426 | Jul 2025 → Mar 2026 overdue | — | Haisco Pharmaceutical Group Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT05135390 | Jun 2022 → Jul 2023 | prurigo nodularis | Haisco Pharmaceutical Group Co., Ltd. | Completed | Met primary |
| Phase 3 | NCT05390905 | Jun → Dec 2022 | — | Haisco Pharmaceutical Group Co., Ltd. | Completed | Met primary |
| Phase 3 | NCT04738357 | Mar → Jul 2021 | — | Haisco Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06359535 | Feb → Nov 2024 | — | Mengchang Yang | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06170476 | Nov 2023 → Feb 2024 | — | Sichuan Provincial People's Hospital | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HSK21542 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04213196 ↗ |
| Known as | anrikefon | “To evaluate the efficacy and safety of anrikefon (formerly known as HSK21542), a novel selective peripherally restricted kappa opioid receptor agonist, in patients with chronic...” PMID 40829896 ↗ Aug 2025 |
| Action | Activate | “a Kappa Receptor Agonist HSK21542” NCT04110886 ↗ |
| Modality | Peptide | “HSK21542, a synthetic short-chain polypeptide” PMID 37833493 ↗ Oct 2023 |
| Route | Other | “Single dose, injection, starting dose of 0.2ug escalating up to 20ug” NCT04110886 ↗ |